Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet-derived growth factor receptor-like 2, pseudogene (PDGFRL2P) is classified as a pseudogene related to the platelet-derived growth factor receptor family. Pseudogenes such as PDGFRL2P arise from gene duplication or retrotransposition but contain inactivating mutations or truncations that typically prevent transcription into functional proteins. PDGFRL2P does not code for an active protein, is not a receptor, and is not considered a therapeutic or pharmacological target. If a biologically relevant gene or active PDGF family receptor was intended, the proper targets would be "Platelet-derived growth factor receptor alpha (PDGFRA)" or "Platelet-derived growth factor receptor beta (PDGFRB)", both of which are functional receptor tyrosine kinases involved in cell proliferation, development, and disease, including cancer and fibrosis[1][2][3][4]. There is no established therapeutic, diagnostic, or safety information specific to PDGFRL2P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet-derived growth factor receptor-like 2, pseudogene (PDGFRL2P).